Search results
Showing 6406 to 6420 of 9123 results
Recommendation ID NG35/1 Question Diagnostic investigations to predict treatment outcomes:- What is the prognostic value of the Hevylite
Recommendation ID NG35/5 Question Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic
Recommendation ID NG35/4 Question Allogeneic stem cell transplantation:- What is the effectiveness of combined autologous–allogeneic stem
Recommendation ID NG25/1 Question Prophylactic cervical cerclage compared with prophylactic vaginal progesterone for preventing preterm
Recommendation ID NG25/4 Question Magnesium sulfate for neuroprotection: bolus plus infusion compared with bolus alone:- What is the clinical
Recommendation ID NG25/3 Question Effectiveness of 'rescue' cerclage:- What is the clinical effectiveness of 'rescue' cerclage in improving
Recommendation ID NG25/2 Question Identifying infection in women with preterm prelabour rupture of membranes (P-PROM):- What is the diagnostic
Recommendation ID IPG652/1 Question Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe
Recommendation ID NG134/4 Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief
Recommendation ID NG85/2 Question Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in
Recommendation ID NG122/1 Question What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell
Recommendation ID IPG619/1 Question Research on the safety and efficacy of superior capsular augmentation for massive rotator cuff tears
Recommendation ID NG50/8 Question Acute hepatic encephalopathy:- In people with cirrhosis and an acute episode of hepatic encephalopathy
Recommendation ID NG52/2 Question Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people
Recommendation ID NG52/1 Question Baseline FDG-PET-CT imaging for people with diffuse large B-cell lymphoma stage II or above:- In people